USPTO serial 79272524
ELEVECTA
Reviewed by CopyMark Law Group
Reg. 6110170Status 739Renewal
- Filing date
- Status date
- Registration date
- Jul 28, 2020
- Examiner
- LEE, DOUGLAS
- Law office
- Historical data usage
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with ELEVECTA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,097*
Plus Government fees of $1,275
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Dyan M. House
Dyan M. House Baker & Mckenzie, LLP1900 N. Pearl Street, Suite 1500Dallas, TX 75201United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical, biological and biochemical reagents for scientific, research, laboratory, industrial and commercial purposes; Chemical, biological and biochemical substances and preparations for scientific, research and laboratory use; chemical, biological and biochemical substances, preparations and reagents for research use in characterizing diseases; chemical, biological and biochemical substances, preparations and reagents for scientific and medical research and drug development; chemical, biological and biochemical substances, preparations and reagents for manufacturing drugs and pharmaceuticals; cultures of microorganisms and viruses, other than for medical or veterinary purposes, in particular adeno-associated viruses; proteins, polypeptides, nucleotides, nucleic acids, eukaryotic cell lines and eukaryotic cells, in particular transfected and/or selected eukaryotic cell lines and eukaryotic cells, other than for medical or veterinary purposes; expression systems in the nature of microorganisms, insect cells, and mammalian cells, for manufacturing stable or transient transfected eukaryotic cell lines and eukaryotic cells, other than for medical or veterinary purposes; expression systems in the nature of microorganisms, insect cells, and mammalian cells for scientific, research, laboratory, industrial and commercial purposes, namely, for manufacturing viral vectors, in particular vectors of adeno-associated viruses | ACTIVE | — |
| 005 | Medicines for the treatment of leukemia, of solid and liquid cancer, of monogenic diseases, of neurological disorders, of neuromuscular disorders, of metabolic disorders, and of viral and infectious diseases; pharmaceutical and veterinary products, preparations and reagents for the treatment of leukemia, of solid and liquid cancer, of monogenic diseases, of neurological disorders, of neuromuscular disorders, of metabolic disorders, and of viral and infectious diseases; chemical, biological and biochemical substances, preparations and reagents for medical and veterinary purposes, namely, for the treatment of leukemia, of solid and liquid cancer, of monogenic diseases, of neurological disorders, of neuromuscular disorders, of metabolic disorders, and of viral and infectious diseases; diagnostic and analytical preparations for medical and veterinary purposes; cultures of microorganisms and viruses for medical or veterinary purposes, in particular adeno-associated viruses; proteins, polypeptides, nucleotides, nucleic acids, eukaryotic cell lines and eukaryotic cells, in particular transfected and/or selected eukaryotic cell lines and eukaryotic cells for medical or veterinary purposes, namely, for the treatment of leukemia, of solid and liquid cancer, of monogenic diseases, of neurological disorders, of neuromuscular disorders, of metabolic disorders, and of viral and infectious diseases; expression systems in the nature of microorganisms, insect cells, and mammalian cells, for manufacturing stable or transient transfected eukaryotic cell lines and eukaryotic cells, for medical and veterinary purposes; expression systems in the nature of microorganisms, insect cells, and mammalian cells, for manufacturing viral vectors, in particular vectors of adeno-associated viruses, for medical, veterinary and medical diagnostic purposes | ACTIVE | — |
| 042 | Scientific and industrial research, in particular in the field of medicine, pharmacy, molecular biology, biotechnology and genetics; research and development of drugs, diagnostic and analytical preparations, therapy procedures, and expression systems in the nature of microorganisms, insect cells, and mammalian cells; scientific, technical and industrial research consultancy, in particular in the field of medicine, pharmacy, molecular biology, biotechnology and genetics; scientific laboratory services, namely, cultivation, extraction, optimization, synthesizing and modifying of eukaryotic cell lines, eukaryotic cells, in particular transfecting and selecting of eukaryotic cells and eukaryotic cell lines with a nucleic acid, in particular a plasmid, viruses, in particular adeno-associated viruses, viral vectors, in particular vectors of adeno-associated viruses, polypeptides, proteins, nucleotides, nucleic acids, for third parties for scientific, research, laboratory, development, industrial and commercial purposes, in particular for use in the field of medicine, pharmacy, molecular biology, biotechnology and genetics; scientific analysis, research and development in the nature of analysis and selection of transfected eukaryotic cells and eukaryotic cell lines and viral vectors, in particular vectors of adeno-associated viruses, for third parties for scientific, research, laboratory, development, industrial and commercial purposes, in particular for use in the field of medicine, pharmacy, molecular biology, biotechnology and genetics | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by CEVEC Pharmaceuticals GmbH
- Other trademarks owned by CEVEC Pharmaceuticals GmbH
- Other trademarks owned by CEVEC Pharmaceuticals GmbH
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named ELEVECTA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 12, 2026 | NA75 | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED | — |
| Jun 12, 2026 | C75A | REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK. | — |
| May 18, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jan 29, 2026 | ES75 | TEAS SECTION 71 & 15 RECEIVED | — |
| Jul 28, 2025 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Oct 18, 2024 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 9, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 9, 2024 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Aug 9, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 9, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 9, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Aug 9, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Nov 19, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 21, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 21, 2023 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Aug 21, 2023 | EWOR | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED | — |
| Aug 21, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 21, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 21, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Aug 21, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jul 13, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 13, 2021 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Jul 13, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 13, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 11, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 11, 2021 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Jun 11, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 11, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 6, 2020 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 17, 2020 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Nov 16, 2020 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 28, 2020 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 28, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 12, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 12, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 22, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 1, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 18, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 17, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 17, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 24, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 3, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 2, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 4, 2019 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 3, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 29, 2019 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 26, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 25, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 21, 2019 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |